EDIT - Editas Medicine, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
EDIT price evolution
EDIT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $64.44 | $69.23 | $123.65 | |
| Short term investments | $214.67 | $226.94 | $199.46 | |
| Net receivables | $0.13 | $0.24 | $0.24 | $10.19 |
| Inventory | ||||
| Total current assets | $271.14 | $286.35 | $305.56 | $340.83 |
| Long term investments | $39.2 | $80.61 | $104.02 | |
| Property, plant & equipment | $51.15 | $51.11 | $44.7 | $45.71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $98.45 | $134.79 | $158.32 | |
| Total investments | $253.87 | $307.55 | $303.48 | |
| Total assets | $327.57 | $384.8 | $440.35 | $499.15 |
| Current liabilities | ||||
| Accounts payable | $12.49 | $13.77 | $7.97 | $8.27 |
| Deferred revenue | $68.89 | $68.89 | $68.89 | |
| Short long term debt | $18.18 | $12.36 | $12.16 | |
| Total current liabilities | $72.35 | $74.31 | $66.49 | $63.22 |
| Long term debt | $20.51 | $21.78 | $24.37 | |
| Total noncurrent liabilities | $78.49 | $79.46 | $86.84 | |
| Total debt | $38.7 | $34.14 | $36.54 | |
| Total liabilities | $151.93 | $152.79 | $145.95 | $150.06 |
| Shareholders' equity | ||||
| Retained earnings | -$1423.05 | -$1360.91 | -$1293.3 | -$1231.35 |
| Other shareholder equity | $0.52 | -$0.44 | -$0.33 | $0.2 |
| Total shareholder equity | $232.01 | $294.4 | $349.1 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $123.65 | $141.52 | $203.52 | $139.68 |
| Short term investments | $199.46 | $202.75 | $296.33 | $262.43 |
| Net receivables | $10.19 | $5.14 | $0.27 | $6.05 |
| Inventory | ||||
| Total current assets | $340.83 | $356.75 | $507.31 | $419.09 |
| Long term investments | $104.02 | $93.1 | $120.07 | $109.66 |
| Property, plant & equipment | $45.71 | $59.22 | $43.29 | $39.15 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $158.32 | $157.57 | $170.17 | $153.51 |
| Total investments | $303.48 | $295.85 | $416.4 | $372.09 |
| Total assets | $499.15 | $514.32 | $677.48 | $572.6 |
| Current liabilities | ||||
| Accounts payable | $8.27 | $9.51 | $5.05 | $6.41 |
| Deferred revenue | $68.89 | $68.89 | $72.22 | $94.93 |
| Short long term debt | $12.16 | $11.08 | $10.31 | $6.81 |
| Total current liabilities | $63.22 | $60.11 | $46.88 | $58.21 |
| Long term debt | $24.37 | $32.86 | $16.07 | $19.32 |
| Total noncurrent liabilities | $86.84 | $93.53 | $76.96 | $120.81 |
| Total debt | $36.54 | $43.95 | $26.38 | $26.14 |
| Total liabilities | $150.06 | $153.64 | $123.84 | $179.02 |
| Shareholders' equity | ||||
| Retained earnings | -$1231.35 | -$1078.13 | -$857.7 | -$665.2 |
| Other shareholder equity | $0.2 | -$3.6 | -$0.49 | -$0.05 |
| Total shareholder equity | $349.1 | $360.68 | $553.64 | $393.59 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.06 | $0.51 | $1.14 | $60.05 |
| Cost of revenue | ||||
| Gross Profit | $0.51 | $1.14 | $60.05 | |
| Operating activities | ||||
| Research & development | $54.21 | $48.79 | $69.56 | |
| Selling, general & administrative | $18.21 | $19.34 | $14.46 | |
| Total operating expenses | $65.73 | $72.42 | $68.13 | $84.01 |
| Operating income | -$71.9 | -$66.99 | -$23.96 | |
| Income from continuing operations | ||||
| EBIT | -$71.9 | -$66.98 | -$23.98 | |
| Income tax expense | ||||
| Interest expense | $3.53 | -$4.3 | -$5.04 | -$5.1 |
| Net income | ||||
| Net income | -$62.14 | -$67.61 | -$61.95 | -$18.87 |
| Income (for common shares) | -$67.61 | -$61.95 | -$18.87 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $78.12 | $19.71 | $25.54 | $90.73 |
| Cost of revenue | ||||
| Gross Profit | $78.12 | $19.71 | $25.54 | $90.73 |
| Operating activities | ||||
| Research & development | $177.65 | $174.96 | $142.51 | $158 |
| Selling, general & administrative | $69.65 | $70.7 | $76.18 | $67.58 |
| Total operating expenses | $247.3 | $245.66 | $218.69 | $225.57 |
| Operating income | -$169.18 | -$225.95 | -$193.15 | -$134.84 |
| Income from continuing operations | ||||
| EBIT | -$170.78 | -$224.66 | -$194.84 | -$118.58 |
| Income tax expense | ||||
| Interest expense | -$17.57 | -$4.22 | -$2.34 | -$2.6 |
| Net income | ||||
| Net income | -$153.22 | -$220.43 | -$192.5 | -$115.98 |
| Income (for common shares) | -$153.22 | -$220.43 | -$192.5 | -$115.98 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$67.61 | -$61.95 | -$18.87 | |
| Operating activities | ||||
| Depreciation | $1.42 | $1.41 | $1.47 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.01 | $7.58 | $5.34 | |
| Total cash flows from operations | -$57.06 | -$49.87 | -$22.24 | |
| Investing activities | ||||
| Capital expenditures | -$3.49 | -$1.87 | -$1.31 | |
| Investments | $55.45 | -$2.87 | $64.15 | |
| Total cash flows from investing | $131.19 | $51.95 | -$4.75 | $62.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.32 | $0.19 | $0.51 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.51 | $0.32 | $0.19 | $0.51 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$27.82 | -$4.79 | -$54.42 | $41.11 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$153.22 | -$220.43 | -$192.5 | -$115.98 |
| Operating activities | ||||
| Depreciation | $6.06 | $6.34 | $5.05 | $3.96 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $19.8 | $29.29 | $43.4 | $23.16 |
| Total cash flows from operations | -$132.18 | -$177.35 | -$163.8 | -$179.84 |
| Investing activities | ||||
| Capital expenditures | -$4.72 | -$4.1 | -$7.98 | -$7.15 |
| Investments | $0.99 | $118.17 | -$46.49 | -$133.37 |
| Total cash flows from investing | -$3.73 | $114.07 | -$54.47 | -$140.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $118.04 | $1.28 | $282.11 | $224.12 |
| Net borrowings | ||||
| Total cash flows from financing | $118.04 | $1.28 | $282.11 | $224.12 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$17.87 | -$62 | $63.84 | -$96.24 |
News
Fundamentals
| Market cap | $85.01M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 82.54M |
| Revenue | $61.76M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$210.57M |
| Revenue Q/Q | -98.86% |
| Revenue Y/Y | 150.95% |
| P/E ratio | -0.40 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.38 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.55 |
|---|---|
| ROA | -50.99% |
| ROE | N/A |
| Debt/Equity | 0.43 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.75 |
| Quick ratio | N/A |